Shruti Sharma
This essay takes stock of the early momentum generated by the joint leaders’ commitment to catalyze public and private investments in building Indian manufacturing capacity—both domestically and in the United States—for active pharmaceutical ingredients (APIs) for critical medicines.
Given the strategic importance of pharmaceutical supply chains to the national security of both India and the United States, and their shared reliance on China for APIs and key starting materials, there is a compelling reason to deepen bilateral cooperation in the pharmaceutical sector. With India as the world’s third-largest producer of medicines by volume and the United States as its largest healthcare market, aligning interests to build a resilient, diversified API ecosystem is both urgent and mutually beneficial.
To discuss this, Carnegie India held a U.S.-India Track 1.5 dialogue during the 9th Global Technology Summit, co-hosted with the Ministry of External Affairs. The discussion brought together stakeholders from government, industry, philanthropic institutions, and the policy community to explore actionable pathways for long-term collaboration on building API supply chain resilience between the two nations.
No comments:
Post a Comment